1-2 of 2
Mark B Geyer, AB
Close
Sort by
Journal Articles

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Monica Bhatia, MD, Mark B Geyer, AB, Courtney Baker, RN, MSN, PNP, Erin Morris, RN, BSN, Deirdre Duffy, BS, Diane George, MD, James H Garvin, Jr., MD, PhD, Prakash Satwani, MD, Joseph Schwartz, MD, Sandra Foley, CPNP, Ria Hawks, CPNP, Elana Hamburger-Smilow, CPNP, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2010) 116 (21): 3504.
https://doi.org/10.1182/blood.V116.21.3504.3504
Published: 2010
Journal Articles

Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

Mark B Geyer, AB, Angela M Ricci, BA, Lauren Harrison, RN, MSN, Deirdre Duffy, BS, Monica Bhatia, MD, James H Garvin, Jr., MD, Diane George, MD, Prakash Satwani, MD, Alexandra C Cheerva, MD, MS, Julie Talano, MD, Fevzi Ozkaynak, MD, Theodore B. Moore, MD, MS, Joseph Schwartz, MD, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2010) 116 (21): 36.
https://doi.org/10.1182/blood.V116.21.36.36
Published: 2010